Breast Cancer Targeted Therapy Selection Test System

2024: Test System Development

In Russia, the first domestic test system has been developed to select targeted therapy for breast cancer (BC). This was announced on October 15, 2024 by specialists from Sechenov University, who created an innovative genetic test of a new generation.

According to the press service of the university, the development is the result of the joint work of the industrial laboratory of applied genomic technologies of the university and the Center for Molecular Oncology "OnkoAtlas." The test system allows not only to detect mutations in genes that provoke the development of hereditary breast cancer, but also at the same time to determine the sensitivity to targeted drugs to prescribe the most effective treatment.

𝓲

Picry.com

Vladislav Mileiko, Deputy Head of the Laboratory of Applied Genomic Technologies of the First Moscow State Medical University, noted that the test system has already been created and is undergoing intermediate validation. Technical and clinical trials are scheduled to begin in early 2025. It is expected that in a year the development will receive a registration certificate from Roszdravnadzor and will become available as part of compulsory medical insurance testing.

The head of the laboratory, director of the Institute of Personalized Oncology of Sechenov University Marina Sekacheva emphasized the uniqueness of the new test system. Unlike existing methods, which only conduct blood tests, the new development allows the detection of mutations in a tumor sample, including both hereditary and acquired ones.

An important feature of the test is the ability to assess the sensitivity of the tumor to targeted drugs and track the effectiveness of treatment. This will allow physicians to obtain complete information to prescribe personalized therapies and predict potential tumor resistance to different treatment regimens.

The developers note that the test system is able to determine the sensitivity of the tumor even to drugs that will enter clinical practice only in a few years. At the same time, it is expected that the cost of research using the new test for patients and the health care system will not increase, and the informativity will increase significantly.^[1]

Notes